ALK and neoplasm: In this work focusing on wild-type NSCLC (ALK and EGFR expression predominantly or 100% negative), ERLO was included although the summary of product characteristics for this drug indicates that “no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with EGFR negative tumours”.